Logo image
Benzoic Acid Derivatives Improve Plasma Stability of Diester Butyrophilin Ligand Prodrugs
Journal article   Open access   Peer reviewed

Benzoic Acid Derivatives Improve Plasma Stability of Diester Butyrophilin Ligand Prodrugs

Parker A. Kintigh, Umed Singh, Girija Pawge, Sidra Bashir, Chia-Hung Christine Hsiao, Andrew J. Wiemer and David F. Wiemer
Journal of medicinal chemistry, Vol.69(4), pp.4329-4345
02/26/2026
DOI: 10.1021/acs.jmedchem.5c03034
PMID: 41680590
url
https://doi.org/10.1021/acs.jmedchem.5c03034View
Published (Version of record) Open Access

Abstract

The potent butyrophilin ligand, (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), is a potential cancer immunotherapy agent, but it lacks plasma stability and membrane permeability. Aryl phosphonamidate prodrugs of a key HMBPP analog have improved plasma stability but poor cellular uptake, while aryl phosphonester prodrugs have improved uptake but lack plasma stability. Here, tuning the benzoic acid substructure of a phosphonester prodrug was explored. Twenty-one aryl phosphonester derivatives were prepared in allylic alcohol (8a–k) and allylic acetate (9a–k) forms. Testing revealed that this strategy can provide compounds with high potency for expansion of γ9δ2 T cells (8d, EC50 = 0.86 nM) and interferon γ production in response to loaded K562 cells (8d, EC50 = 2.3 nM). Importantly, these compounds display improved plasma stability (130-fold range; 8d, t 1/2 > 24 h), showing the importance of the benzoic acid position for plasma versus cellular metabolism. These findings enable next-generation prodrugs with improved stability and potency.

Details

Metrics

1 Record Views
Logo image